News
The day at a glance · 3 min read
Mood · Cautious
+15
Sentiment, −100 to +100
J&J 2Q26 Sales Growth
6.6%
J&J Close
$252.83-1.25%
AbbVie Close
$265.85+1.15%
Key driverClinical trial partnerships and patent cliff analysis drive mixed sector performance amid regulatory developments
Daily briefHealthcare· Money365.Market AI ·

Thermo Fisher Partners Lift Biotech Trials; J&J Faces Cliff

CRO deals accelerate MS program while patent expirations test Big Pharma replacement engines

Big Pharma & Biotech

Neutral

Genmab Jump

10.7%
JNJABBVBMY
Johnson & Johnson ($JNJ) reported second-quarter 2026 sales growth of 6.6% despite headwinds from STELARA, according to analysis examining the company's patent cliff challenges and replacement pipeline. The stock closed down 1.25% at $252.83 in the latest trading session, underperforming the broader market. Analysts are evaluating whether J&J's replacement engine can offset upcoming patent expirations as key revenue contributors face exclusivity losses.
AbbVie ($ABBV) shares closed up 1.15% at $265.85, outpacing the broader market. Partner Genmab shares jumped 10.7% on above-average trading volume following positive data showing its Epkinly antibody, combined with standard lymphoma drugs, helped patients live longer before disease worsening. Epkinly is positioned as a $3 billion cancer contender in AbbVie's oncology portfolio, with analysts suggesting earnings estimate revisions could drive further strength.
Bristol-Myers Squibb ($BMY) was highlighted in screening coverage as analysts evaluate dividend-focused defensive positioning in the current market environment. The stock appeared in coverage alongside other stocks as investors assess pharmaceutical sector exposure amid softer rate hike expectations and a more cautious Federal Reserve stance.

Clinical Trials & CRO Services

Bullish
QNTMTMO
Quantum BioPharma ($QNTM) has partnered with the clinical research division of Thermo Fisher Scientific ($TMO) to launch a Phase 2 clinical trial for Lucid-MS, its progressive multiple sclerosis treatment, according to an exclusive announcement. The companies signed a Study Start-Up Agreement marking a major developmental milestone following FDA clearance of the therapy. Thermo Fisher's PPD clinical research business will handle formal study initiation and provide related research services.
Thermo Fisher Scientific ($TMO) is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotechnology companies navigate increasingly complex paths to commercialization at CPHI Milan 2026, held October 6-8. The company is showcasing new solutions designed to reduce friction and maintain momentum for clients. Thermo Fisher was highlighted in industry outlook coverage alongside Globus Medical and Intuitive Surgical as a key player in healthcare services and medical technology.

MedTech & Surgical Robotics

Bullish
ISRG
Intuitive Surgical ($ISRG) was analyzed as a wide-moat leader in robotic surgery with strong secular tailwinds and high recurring revenue potential, despite a compression in its valuation multiple. Coverage emphasized that while the stock's multiple has fallen, the underlying competitive story and market position remain intact. The company was included in industry outlook analysis alongside Globus Medical and Thermo Fisher Scientific as a key medical technology innovator.

Health Insurance & Managed Care

Neutral

UNH Recent Close

$371.90+3.66%

UNH 12-Month Low

$255.97

UNH 12-Month High

$461.62
UNH
UnitedHealth Group ($UNH) closed at $371.90 on October 2, up 3.66% over the trailing twelve-month period, according to analysis examining the stock's investment merits at current levels. The shares have traded in a range from a low of $255.97 to a high of $461.62 within those twelve months, representing more than two hundred dollars of volatility on a company whose revenue barely moved. Analysts noted that margin performance explains the significant price range despite relatively stable top-line revenue trends.
UnitedHealth ($UNH) appeared in defensive dividend stock screening coverage as investors evaluate income-focused positioning amid cooling economic data and softer Federal Reserve rate expectations. The managed care leader was highlighted alongside other dividend-paying defensive names as a potential beneficiary of a calmer macro backdrop that could support steadier payers.

Biotech Developments

Neutral
CGENBMRN
Compugen ($CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen research during a company update event. The biotech is advancing its oncology pipeline while leveraging artificial intelligence to identify new therapeutic targets in cancer treatment.
BioMarin Pharmaceutical ($BMRN) appointed Cara Bauer as Executive Vice President and Chief People Officer, effective October 5. Bauer assumes responsibility for the company's Human Resources organization, succeeding Amy Wireman, who is retiring from the rare disease specialist.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy